Victor Ibubeleye

• BSc (Hons) Pharmacology
• Determination of the relationship between CYP2C9 genotypes and daily warfarin dose requirement in patients on anticoagulation therapy

Warfarin is used to treat blood clotting disorders in children. It is broken down by the enzyme CYP2C9. There are mutations in the gene that expresses CYP2C9 resulting in potentially slower elimination of warfarin. Some children are more sensitive to warfarin than others and are thus liable to bleed due to excessive thinning of the blood. This research will assess the effect of CYP2C9 genotype on warfarin dose requirement in a group of children. The establishment of a relationship between CYP2C9 and warfarin dosage is important in identifying the impact of genetics on sensitivity to warfarin in children.

Funding Source: Wellcome Trust